Pairwise Cox proportional hazards models
| . | Patients . | Pairwise multivariate analysis . | |||
|---|---|---|---|---|---|
| Variable . | No. . | % . | HR . | 95% CI . | P value . |
| Pairwise analysis 1 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.8 | 1.1-3.1 | .02 |
| Age > 45 y | 61 | 22 | 1.9 | 1.2-3.2 | .01 |
| Pairwise analysis 2 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.9 | 1.1-3.1 | .02 |
| Male gender | 154 | 56 | 1.7 | 1.0-2.9 | .03 |
| Pairwise analysis 3 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.8 | 1.1-3.1 | .02 |
| Stage IV disease | 82 | 30 | 1.7 | 1.1-2.8 | .03 |
| Pairwise analysis 4 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 2.0 | 1.2-3.3 | .01 |
| Albumin < 4 g/dL | 185 | 68 | 1.2 | 0.7-2.1 | .45 |
| Pairwise analysis 5 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.9 | 1.1-3.2 | .02 |
| Hemoglobin < 10.5 g/L | 52 | 19 | 1.5 | 0.9-2.6 | .15 |
| Pairwise analysis 6 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 2.1 | 1.2-3.6 | .01 |
| Leukocytosis ≥ 15 000 WBCs/mm3 | 45 | 16 | 1.4 | 0.8-2.7 | .27 |
| Pairwise analysis 7 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 2.0 | 1.2-3.4 | .01 |
| Lymphocytes < 600/mm3 or < 8% WBCs | 62 | 23 | 1.3 | 0.8-2.3 | .27 |
| . | Patients . | Pairwise multivariate analysis . | |||
|---|---|---|---|---|---|
| Variable . | No. . | % . | HR . | 95% CI . | P value . |
| Pairwise analysis 1 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.8 | 1.1-3.1 | .02 |
| Age > 45 y | 61 | 22 | 1.9 | 1.2-3.2 | .01 |
| Pairwise analysis 2 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.9 | 1.1-3.1 | .02 |
| Male gender | 154 | 56 | 1.7 | 1.0-2.9 | .03 |
| Pairwise analysis 3 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.8 | 1.1-3.1 | .02 |
| Stage IV disease | 82 | 30 | 1.7 | 1.1-2.8 | .03 |
| Pairwise analysis 4 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 2.0 | 1.2-3.3 | .01 |
| Albumin < 4 g/dL | 185 | 68 | 1.2 | 0.7-2.1 | .45 |
| Pairwise analysis 5 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 1.9 | 1.1-3.2 | .02 |
| Hemoglobin < 10.5 g/L | 52 | 19 | 1.5 | 0.9-2.6 | .15 |
| Pairwise analysis 6 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 2.1 | 1.2-3.6 | .01 |
| Leukocytosis ≥ 15 000 WBCs/mm3 | 45 | 16 | 1.4 | 0.8-2.7 | .27 |
| Pairwise analysis 7 | |||||
| Pretreatment plasma EBV(+) | 54 | 20 | 2.0 | 1.2-3.4 | .01 |
| Lymphocytes < 600/mm3 or < 8% WBCs | 62 | 23 | 1.3 | 0.8-2.3 | .27 |
Pairwise multivariate analyses were performed for the cohort of 274 patients with pretreatment plasma specimens and each IPS factor, using Cox proportional hazard regression models. Pretreatment plasma EBV(+) was defined as >60 viral copies/100 μL of plasma. P values are for the correlation between each variable and FFS.
CI, confidence interval; HR, hazard ratio; WBC, white blood cells.